Amgen (AMGN) Current Assets (2009 - 2026)
Amgen (AMGN) posted quarterly Current Assets of $31.5 billion for Q1 2026, up 16.88% year-over-year from $26.9 billion in Q1 2025, and up 8.32% quarter-over-quarter from $29.1 billion in Q4 2025.
Amgen (AMGN) Current Assets (2009 - 2026) Analysis & Trends
Amgen's Current Assets history runs 18 years deep, the most recent figure standing at $31.5 billion for Q1 2026.
- In Q1 2026, Current Assets rose 16.88% year-over-year to $31.5 billion; the TTM figure through Mar 2026 stood at $31.5 billion (up 16.88% YoY), while the FY2025 annual figure was $29.1 billion, changed 0.09% from the prior year.
- Current Assets for Q1 2026 stood at $31.5 billion, up from $29.1 billion in the prior quarter.
- The five-year high for Current Assets was $48.5 billion in Q3 2023, with the low at $18.5 billion in Q1 2022.
- The 5-year median for Current Assets is $27.9 billion (2025), against an average of $29.9 billion.
- The sharpest annual moves came in 2023 and 2024: Current Assets jumped 145.21% in 2023, then sank 44.79% in 2024.
- Amgen's Current Assets stood at $22.2 billion in 2022, then surged by 36.72% to $30.3 billion in 2023, then decreased by 4.29% to $29.0 billion in 2024, then grew by 0.09% to $29.1 billion in 2025, then gained by 8.32% to $31.5 billion in 2026.
- Business Quant data shows AMGN's Current Assets at $31.5 billion in Q1 2026, $29.1 billion in Q4 2025, and $27.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 27.97 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 34.96 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 13.95 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 41.36 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 23.56 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 36.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.96 Bn |
| Mar 31, 2026 | 31.48 Bn |
| Dec 31, 2025 | 29.06 Bn |
| Sep 30, 2025 | 27.89 Bn |
| Jun 30, 2025 | 26.73 Bn |
| Mar 31, 2025 | 26.93 Bn |
| Dec 31, 2024 | 29.03 Bn |
| Sep 30, 2024 | 26.77 Bn |
| Jun 30, 2024 | 27.21 Bn |
| Mar 31, 2024 | 28.03 Bn |
| Dec 31, 2023 | 30.33 Bn |
| Sep 30, 2023 | 48.48 Bn |
| Jun 30, 2023 | 47.38 Bn |
| Mar 31, 2023 | 44.70 Bn |
| Dec 31, 2022 | 22.19 Bn |
| Sep 30, 2022 | 24.06 Bn |
| Jun 30, 2022 | 19.32 Bn |
| Mar 31, 2022 | 18.52 Bn |
| Dec 31, 2021 | 19.39 Bn |
| Sep 30, 2021 | 24.38 Bn |